Currently out of the existing stock ratings of Pasha Sarraf, 3 are a HOLD (37.5%), 5 are a BUY (62.5%).

Pasha Sarraf

Work Performance Price Targets & Ratings Chart

Analyst Pasha Sarraf, currently employed carries an average stock price target met ratio of 83.33% that have a potential upside of 61.28% achieved within 433 days. Previously, Pasha Sarraf worked at LEERINK.

Pasha Sarraf’s has documented 14 price targets and ratings displayed on 3 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ACRS, Aclaris Therapeutics at 04-Mar-2021.

Wall Street Analyst Pasha Sarraf

Analyst best performing recommendations are on ACRS (ACLARIS THERAPEUTICS).
The best stock recommendation documented was for ACRS (ACLARIS THERAPEUTICS) at 3/4/2021. The price target of $26 was fulfilled within 15 days with a profit of $4.86 (22.99%) receiving and performance score of 15.33.

Average potential price target upside

ACRS Aclaris Therapeutics PRVB Provention Bio VKTX Viking Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

2 months 3 days ago
(17-Sep-2024)

0/5 (0%)

$34.34 (396.54%)

Hold

10 months 9 days ago
(11-Jan-2024)

0/2 (0%)

$21.59 (291.36%)

Hold

$1.5

10 months 10 days ago
(10-Jan-2024)

1/4 (25%)

$0.49 (48.51%)

315

Hold

$1

$-1.05 (-51.22%)

$2

11 months 2 days ago
(18-Dec-2023)

2/4 (50%)

$0.06 (6.38%)

178

Hold

$38

1 years 6 days ago
(14-Nov-2023)

0/7 (0%)

$23.92 (169.89%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Pasha Sarraf?

On 2019

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?